These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 15714077

  • 21. Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience.
    Grigorescu Sido P, Drugan C, Cret V, Al-Kzouz C, Denes C, Coldea C, Zimmermann A.
    J Inherit Metab Dis; 2007 Oct; 30(5):783-9. PubMed ID: 17703370
    [Abstract] [Full Text] [Related]

  • 22. [French results of enzyme replacement therapy in Gaucher's disease].
    Schaison G, Caubel I, Belmatoug N, Billette de Villemeur T, Saudubray JM.
    Bull Acad Natl Med; 2002 Oct; 186(5):851-61; discussion 861-3. PubMed ID: 12412377
    [Abstract] [Full Text] [Related]

  • 23. Imiglucerase in the treatment of Gaucher disease: a history and perspective.
    Deegan PB, Cox TM.
    Drug Des Devel Ther; 2012 Oct; 6():81-106. PubMed ID: 22563238
    [Abstract] [Full Text] [Related]

  • 24. Interruption of enzyme replacement therapy in Gaucher disease.
    Goldblatt J, Fletcher JM, McGill J, Szer J, Wilson M.
    S Afr Med J; 2016 May 25; 106(6 Suppl 1):S79-81. PubMed ID: 27245534
    [Abstract] [Full Text] [Related]

  • 25. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
    Mistry PK, Weinreb NJ, Kaplan P, Cole JA, Gwosdow AR, Hangartner T.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):66-72. PubMed ID: 21112800
    [Abstract] [Full Text] [Related]

  • 26. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.
    Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ.
    Br J Haematol; 2009 Nov 15; 147(4):561-70. PubMed ID: 19732054
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Mistry PK, Batista JL, Andersson HC, Balwani M, Burrow TA, Charrow J, Kaplan P, Khan A, Kishnani PS, Kolodny EH, Rosenbloom B, Scott CR, Weinreb N.
    Am J Hematol; 2017 Sep 15; 92(9):929-939. PubMed ID: 28569047
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Baseline characteristics of 32 patients with Gaucher disease who were treated with imiglucerase: South African data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Sevittz H, Laher F, Varughese ST, Nel M, McMaster A, Jacobson BF.
    S Afr Med J; 2022 Feb 02; 112(1):13518. PubMed ID: 35140000
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Enzyme replacement therapy with imiglucerase in a Taiwanese child with type 1 Gaucher disease.
    Lin HY, Lin SP, Chuang CK, Wraith JE.
    J Chin Med Assoc; 2006 May 02; 69(5):228-32. PubMed ID: 16835986
    [Abstract] [Full Text] [Related]

  • 34. EVALUATION OF EFFICIENCY OF IMIGLUCERASE (CEREZYME) IN THE TREATMENT OF GAUCHER DISEASE (CASE REPORTS AND REVIEW OF THE LITERATURE).
    Samohalska O, Kornaga S, Mandziy Z, Boiko T, Radetska L.
    Georgian Med News; 2018 Feb 02; (Issue):69-73. PubMed ID: 29578427
    [Abstract] [Full Text] [Related]

  • 35. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources.
    Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, Parker C, Schiffmann R, Hill SC, Brady RO.
    Ann Intern Med; 1995 Jan 01; 122(1):33-9. PubMed ID: 7985893
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause).
    Zimran A, Morris E, Mengel E, Kaplan P, Belmatoug N, Hughes DA, Malinova V, Heitner R, Sobreira E, Mrsić M, Granovsky-Grisaru S, Amato D, vom Dahl S.
    Blood Cells Mol Dis; 2009 Jan 01; 43(3):264-88. PubMed ID: 19502088
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. First long-term results of imiglucerase therapy of type 1 Gaucher disease.
    Niederau C, vom Dahl S, Häussinger D.
    Eur J Med Res; 1998 Feb 21; 3(1-2):25-30. PubMed ID: 9512964
    [Abstract] [Full Text] [Related]

  • 40. Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease.
    Elstein D, Abrahamov A, Hadas-Halpern I, Meyer A, Zimran A.
    QJM; 1998 Jul 21; 91(7):483-8. PubMed ID: 9797931
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.